Suzhou Zelgen Biopharmaceuticals Co., Ltd

The company was founded in 2009 and is committed to independent R&D, production and commercialization of innovative drugs. The company aims to become a leading enterprise in the development and production of new drugs in the fields of oncology, hemorrhagic and hematologic diseases, immune inflammatory diseases, and hepatobiliary diseases in China. The company's market strategy is to face the world, focus on China, develop and produce innovative drugs with independent intellectual property rights, safe, effective, and affordable to patients to meet the huge domestic and foreign pharmaceutical market needs. The company is an innovative pharmaceutical company focusing on various treatment fields such as tumors, hemorrhagic and hematologic diseases, immune inflammatory diseases, and hepatobiliary diseases. Main products: donafenib toluene sulfonate tablets, jacketinib hydrochloride tablets, recombinant human thrombin, injectable recombinant human thyroid-stimulating hormone, 8 products in clinical phase I/II, etc. The company has successively completed 5 national “major new drug creations”, 1 national science and technology innovation fund for small and medium-sized enterprises, and a number of Jiangsu provincial science and technology projects; the company has applied for 286 invention patents, of which 115 have been granted invention patents in China, the United States, the European Union and other countries and regions.